Sign In
Buy KALV
$26.95
+0.0100 (+0.0371%)
At Close: Jun 03, 2026
KalVista Pharmaceuticals to Present at Upcoming Investor Conferences
07:00am, Wednesday, 25'th Feb 2026
FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the Company will participate in a fireside chat at each of the following up
Wall Street Analysts Think KalVista Pharmaceuticals (KALV) Could Surge 117.1%: Read This Before Placing a Bet
10:55am, Tuesday, 24'th Feb 2026
The consensus price target hints at an 117.1% upside potential for KalVista Pharmaceuticals (KALV). While empirical research shows that this sought-after metric is hardly effective, an upward trend in
FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the newly published International Guideline on the Diagnosis and Management
Financial Survey: SCYNEXIS (NASDAQ:SCYX) and KalVista Pharmaceuticals (NASDAQ:KALV)
01:58am, Monday, 16'th Feb 2026
KalVista Pharmaceuticals (NASDAQ: KALV - Get Free Report) and SCYNEXIS (NASDAQ: SCYX - Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the tw
FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the acceptance of three abstracts for presentation at the 2026 American Academy o
KalVista: Next Stage Of Growth For EKTERLY Lies With Pediatric Label Expansion
03:39pm, Wednesday, 11'th Feb 2026
KalVista Pharmaceuticals retains a 'Strong Buy' rating, driven by EKTERLY's global launch and robust initial sales momentum. Company achieved $35M in Q4 2025 and $49M in full-year 2025 unaudited EKTER
KalVista Pharmaceuticals (NASDAQ:KALV) vs. Enanta Pharmaceuticals (NASDAQ:ENTA) Financial Review
01:34am, Thursday, 05'th Feb 2026
KalVista Pharmaceuticals (NASDAQ: KALV - Get Free Report) and Enanta Pharmaceuticals (NASDAQ: ENTA - Get Free Report) are both small-cap medical companies, but which is the better business? We will co
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07:00am, Tuesday, 03'rd Feb 2026
FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the Compensation Committee of KalVista's Board of Directors granted six new
Wall Street Analysts Believe KalVista Pharmaceuticals (KALV) Could Rally 116.4%: Here's is How to Trade
10:55am, Monday, 02'nd Feb 2026
The consensus price target hints at an 116.4% upside potential for KalVista Pharmaceuticals (KALV). While empirical research shows that this sought-after metric is hardly effective, an upward trend in
Emerald Advisers LLC Grows Position in KalVista Pharmaceuticals, Inc. $KALV
04:53am, Thursday, 22'nd Jan 2026
Emerald Advisers LLC raised its holdings in shares of KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) by 30.2% during the third quarter, according to its most recent filing with the SEC. The firm owned
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives Average Recommendation of “Moderate Buy” from Brokerages
01:22am, Friday, 16'th Jan 2026
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV - Get Free Report) has been given an average rating of "Moderate Buy" by the nine research firms that are presently covering the stock, MarketBeat Ratings
Does KalVista Pharmaceuticals (KALV) Have the Potential to Rally 117.98% as Wall Street Analysts Expect?
10:56am, Thursday, 15'th Jan 2026
The mean of analysts' price targets for KalVista Pharmaceuticals (KALV) points to an 118% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreeme
KalVista Details Early Sales, Prescriber Uptake For Newly Approved Rare Swelling Drug
09:56am, Friday, 09'th Jan 2026
KalVista Pharmaceuticals Inc. (NASDAQ: KALV) on Thursday reported early commercial momentum for its hereditary angioedema treatment EKTERLY, highlighting growing prescriber adoption, repeat prescripti
U.S. stock futures pared earlier losses to advance on Friday after a mixed Thursday. Futures of major benchmark indices were trading higher.
KalVista Pharmaceuticals Provides Update on Strong EKTERLY® Launch with Preliminary Fourth Quarter and Full Year 2025 Revenue Results
04:05pm, Thursday, 08'th Jan 2026
FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today provided its preliminary fourth quarter and full year ended December 31, 2025 unaudited gl
